| Overexpressed-eIF3I interacted and activated oncogenic Akt1 is a theranostic target in human hepatocellular carcinoma. | liver, |
| Transcriptional regulation of serine/threonine protein kinase (AKT) genes by glioma-associated oncogene homolog 1. | glioma, |
| we showed that the synergism between HIV-1 Nef and Kaposi_s sarcoma-associated herpesvirus IL-6 in the promotion of angiogenesis and oncogenesis depends on the AKT signaling pathway | sarcoma, |
| Oncogenic B-Raf(V600E) abrogates the AKT/B-Raf/Mps1 interaction in melanoma cells. | skin, |
| AKT1 E17K is a bona fide oncogene in a human luminal breast cancer context. Distinct PI3K pathway mutations confer differential sensitivity to drugs targeting the pathway at different points and by distinct mechanisms. | breast, |
| PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system. | breast, |
| Carboxyl-terminal modulator protein positively regulates Akt phosphorylation and acts as an oncogenic driver in breast cancer. | breast, |
| Androgen receptor promotes the oncogenic function of overexpressed Jagged1 in prostate cancer by enhancing cyclin B1 expression via Akt phosphorylation. | prostate, |
| Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia. | leukemia, |
| The survival of CSF1R(pos) cells requires active AKT (v-akt murine thymoma viral oncogene homolog 1) signaling, which contributed to increased levels of nuclear, transcriptionally competent beta-catenin. | thymoma, |
| Autocrine CSF-1R signaling drives mesothelioma chemoresistance via AKT activation. | mesothelioma, |
| AKT-mTOR pathway is a novel component of oncogene induced DNA damage response in immortalized _normal-like_ breast cells and its suppression may contribute to growth arrest and arrest of the breast tumorigenesis | breast, |
| Suppression of Akt-mTOR pathway-a novel component of oncogene induced DNA damage response barrier in breast tumorigenesis. | breast, |
| miR-99a suppresses the metastasis of human non-small cell lung cancer cells by targeting AKT1 signaling pathway. | lung, |
| WWP1 as a potential tumor oncogene regulates PTEN-Akt signaling pathway in human gastric carcinoma. | gastric, |
| Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines. | lung, |
| Data suggest that expression, processing, and activation of (that is, signal transduction via) Notch1 (neurogenic locus notch homolog protein 1), Pten (phosphatase and tensin homolog), and Akt1 (thymoma viral proto-oncogene 1) are involved in oogenesis; oogenesis proceeds via both recruitment of primordial follicles and proliferation of granulosa cells. | thymoma, |
| Data indicate that phosphorylation status of proto-oncogene c-AKT(Ser473) serves as a biomarker to identify advanced head and neck squamous cell carcinoma (HNSCC) patients at high risk for radiotherapy treatment failure. | HNSC, |
| Phosphorylation of AKT(Ser473) serves as an independent prognostic marker for radiosensitivity in advanced head and neck squamous cell carcinoma. | HNSC, |
| Data show that serine/threonine kinase LKB1 and proto-oncogene protein Akt are targets of neddylation, suggesting the post-translational modification (PTM) as a potential therapeutic target during liver tumor management and treatment. | liver, |